

**UroGen Pharma Ltd.  
9 Ha'Ta'asiya Street  
Ra'anana 4365007, Israel**

**VIA EDGAR**

May 1, 2017

United States Securities and Exchange Commission  
Division of Corporation Finance  
Mail Stop 4561  
100 F Street, N.E.  
Washington, D.C. 20549

Attention: Ms. Suzanne Hayes  
Mr. Joseph McCann  
Mr. Joshua Samples  
Mr. Mark Brunhofer  
Mr. James Rosenberg

**Re: UroGen Pharma Ltd.  
Acceleration Request for Registration Statement on Form F-1  
File No. 333-217201**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "**Act**"), UroGen Pharma Ltd. (the "**Company**") hereby requests that the effective date of the above-referenced registration statement (the "**Registration Statement**") be accelerated to May 3, 2017, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Cooley LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Cooley LLP, by calling Joshua A. Kaufman at (212) 479-6495, or in his absence, Barbara H. Bispham at (212) 479-6727.

If you have any questions regarding this request, please contact Joshua A. Kaufman of Cooley LLP at (212) 479-6495 or Barbara Bispham of Cooley LLP at (212) 479-6727. Thank you for your assistance with this matter.

Sincerely,

UROGEN PHARMA LTD.

/s/ Ron Bentsur

---

Ron Bentsur  
Chief Executive Officer

cc: Ron Bentsur, *UroGen Pharma Ltd.*  
Joshua A. Kaufman, *Cooley LLP*  
Divakar Gupta, *Cooley LLP*  
Daniel I. Goldberg, *Cooley LLP*